Reports related to this article:
Project(s): View 2 related projects in PECWeb
Plant(s): View 2 related plants in PECWeb
Released August 20, 2024 | NEW DELHI
en
August 20, 2024--Researched by Industrial Info Resources (Sugar Land, Texas)--Monoclonal antibodies (mAbs) have transformed the medical sector by offering targeted treatment options for a wide range of diseases. Produced in laboratories, mAbs act like natural antibodies that can restore, enhance or mimic the immune system's ability to identify and neutralize specific antigens (which are proteins on the surface of cells). By precisely targeting these antigens, mAbs provide focused treatment for various illnesses.
Since mAbs have higher specificity and efficacy with fewer side effects than traditional therapies, they are capable of significantly improving patient outcomes, thus leading to increased demand for personalized medicine. Consequently, this heightened interest in personalized treatment is fueling substantial investments in the global monoclonal antibody market.
Oncology, immunology and infectious diseases are the key segments driving the mAbs therapeutics market. Monoclonal antibodies have transformed cancer treatment with targeted therapies that enhance patient outcomes and minimize side effects. For the treatment of autoimmune disorders like rheumatoid arthritis and lupus, mAbs help by inhibiting specific immune system components. The rise of infectious diseases has further accelerated the development of monoclonal antibodies to identify and eliminate harmful pathogens, addressing both existing and newly emerging health crises.
Industrial Info is tracking 36 active capital spending projects with investments of US$7.74 billion geared toward the mAbs immunotherapeutic market. Approximately 46% of the spending is geared for grassroot projects while around 53% is directed toward expanding existing facilities. Subscribers to Industrial Info's Global Market Intelligence (GMI) Pharmaceutical & Biotech Project Database can click here for a list of detailed project reports.
By region, Asia dominates the market with investments totaling US$4 billion, accounting for about 53.76% of the total potential global spending. Europe follows with an investment of about US$3 billion.
Lithuania, Singapore and China are the top countries that are driving significant spending in the mAb therapeutics market. With investments worth US$2.5 billion Lithuania is the leading investor. Singapore and China follow with spending amounting up to US$2 billion and US$1 billion, respectively.
Northway Biotech, Astrazeneca PLC, Lakes Bioscience Limited, Piramal Enterprises Limited and Novartis Group AG are the key players that are making heavy investments toward the production of mAb immunotherapeutics.
With an investment of US$2 billion, Astrazeneca Singapore Private Limited in Singapore is aiming to invest in the mAbs therapeutics market to construct an end-to-end manufacturing facility for novel antibody drug conjugates focusing on the production of chemotherapy drug and linker, linker antibody, and filling, featuring robotic, automated, and cognitive technology, with employment of net-zero environmental goals (including solar and wastewater treatment features). Subscribers can click here for the project report.
Northway Biotech is the leading company in Europe, with investments worth US$2.5 billion aimed at the Vilnius Bio City Large-Scale Mammalian Production Centre Addition Phase VI expansion project. With a focus on diseases like cancer, asthma and other inflammatory conditions, the project is geared toward the development and manufacturing of therapeutic monoclonal antibodies in the Lithuania region. Subscribers can click here for the project report.
Around 70% of the total investments are still in the initial planning stage, 6% are undergoing engineering and the rest are in the construction phases. Cost-related challenges persist due to the high expenses involved in research, preclinical studies, clinical trials and manufacturing processes. This in turn ultimately limits the accessibility and affordability of treatments.
Subscribers can click here for a list of all project reports mentioned in this article and click here for the related plant profiles.
Industrial Info Resources (IIR) is the leading provider of industrial market intelligence. Since 1983, IIR has provided comprehensive research, news and analysis on the industrial process, manufacturing and energy related industries. IIR's Global Market Intelligence (GMI) helps companies identify and pursue trends across multiple markets with access to real, qualified and validated plant and project opportunities. Across the world, IIR is tracking more than 200,000 current and future projects worth $17.8 Trillion (USD).
Since mAbs have higher specificity and efficacy with fewer side effects than traditional therapies, they are capable of significantly improving patient outcomes, thus leading to increased demand for personalized medicine. Consequently, this heightened interest in personalized treatment is fueling substantial investments in the global monoclonal antibody market.
Oncology, immunology and infectious diseases are the key segments driving the mAbs therapeutics market. Monoclonal antibodies have transformed cancer treatment with targeted therapies that enhance patient outcomes and minimize side effects. For the treatment of autoimmune disorders like rheumatoid arthritis and lupus, mAbs help by inhibiting specific immune system components. The rise of infectious diseases has further accelerated the development of monoclonal antibodies to identify and eliminate harmful pathogens, addressing both existing and newly emerging health crises.
Industrial Info is tracking 36 active capital spending projects with investments of US$7.74 billion geared toward the mAbs immunotherapeutic market. Approximately 46% of the spending is geared for grassroot projects while around 53% is directed toward expanding existing facilities. Subscribers to Industrial Info's Global Market Intelligence (GMI) Pharmaceutical & Biotech Project Database can click here for a list of detailed project reports.
By region, Asia dominates the market with investments totaling US$4 billion, accounting for about 53.76% of the total potential global spending. Europe follows with an investment of about US$3 billion.
Lithuania, Singapore and China are the top countries that are driving significant spending in the mAb therapeutics market. With investments worth US$2.5 billion Lithuania is the leading investor. Singapore and China follow with spending amounting up to US$2 billion and US$1 billion, respectively.
Northway Biotech, Astrazeneca PLC, Lakes Bioscience Limited, Piramal Enterprises Limited and Novartis Group AG are the key players that are making heavy investments toward the production of mAb immunotherapeutics.
With an investment of US$2 billion, Astrazeneca Singapore Private Limited in Singapore is aiming to invest in the mAbs therapeutics market to construct an end-to-end manufacturing facility for novel antibody drug conjugates focusing on the production of chemotherapy drug and linker, linker antibody, and filling, featuring robotic, automated, and cognitive technology, with employment of net-zero environmental goals (including solar and wastewater treatment features). Subscribers can click here for the project report.
Northway Biotech is the leading company in Europe, with investments worth US$2.5 billion aimed at the Vilnius Bio City Large-Scale Mammalian Production Centre Addition Phase VI expansion project. With a focus on diseases like cancer, asthma and other inflammatory conditions, the project is geared toward the development and manufacturing of therapeutic monoclonal antibodies in the Lithuania region. Subscribers can click here for the project report.
Around 70% of the total investments are still in the initial planning stage, 6% are undergoing engineering and the rest are in the construction phases. Cost-related challenges persist due to the high expenses involved in research, preclinical studies, clinical trials and manufacturing processes. This in turn ultimately limits the accessibility and affordability of treatments.
Subscribers can click here for a list of all project reports mentioned in this article and click here for the related plant profiles.
Industrial Info Resources (IIR) is the leading provider of industrial market intelligence. Since 1983, IIR has provided comprehensive research, news and analysis on the industrial process, manufacturing and energy related industries. IIR's Global Market Intelligence (GMI) helps companies identify and pursue trends across multiple markets with access to real, qualified and validated plant and project opportunities. Across the world, IIR is tracking more than 200,000 current and future projects worth $17.8 Trillion (USD).
